173 related articles for article (PubMed ID: 35461262)
1. Efficacy and safety of scopolamine compared to placebo in individuals with bipolar disorder who are experiencing a depressive episode (SCOPE-BD): study protocol for a randomised double-blind placebo-controlled trial.
Miravalles C; Kane R; McMahon E; McDonald C; Cannon DM; Hallahan B
Trials; 2022 Apr; 23(1):339. PubMed ID: 35461262
[TBL] [Abstract][Full Text] [Related]
2. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial.
Furey ML; Drevets WC
Arch Gen Psychiatry; 2006 Oct; 63(10):1121-9. PubMed ID: 17015814
[TBL] [Abstract][Full Text] [Related]
4. A randomised, double-blind, active placebo-controlled, parallel groups, dose-response study of scopolamine hydrobromide (4-6 μg/kg) in patients with major depressive disorder.
Chen JCC; Sumner RL; Krishnamurthy Naga V; Hoeh N; Ayeni HA; Singh V; Sundram F; Campbell D; Muthukumaraswamy S
Trials; 2020 Feb; 21(1):157. PubMed ID: 32041658
[TBL] [Abstract][Full Text] [Related]
5. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
[TBL] [Abstract][Full Text] [Related]
6. ECNP consensus meeting. Bipolar depression. Nice, March 2007.
Goodwin GM; Anderson I; Arango C; Bowden CL; Henry C; Mitchell PB; Nolen WA; Vieta E; Wittchen HU
Eur Neuropsychopharmacol; 2008 Jul; 18(7):535-49. PubMed ID: 18501566
[TBL] [Abstract][Full Text] [Related]
7. Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression.
Yatham LN; Arumugham SS; Kesavan M; Ramachandran K; Murthy NS; Saraf G; Ouyang Y; Bond DJ; Schaffer A; Ravindran A; Ravindran N; Frey BN; Daigneault A; Beaulieu S; Lam RW; Kondapuram N; Reddy MS; Bhandary RP; Ashok MV; Ha K; Ahn YM; Milev R; Wong H; Reddy YCJ;
N Engl J Med; 2023 Aug; 389(5):430-440. PubMed ID: 37530824
[TBL] [Abstract][Full Text] [Related]
8. Effects of recombinant human erythropoietin on cognition and neural activity in remitted patients with mood disorders and first-degree relatives of patients with psychiatric disorders: a study protocol for a randomized controlled trial.
Petersen JZ; Schmidt LS; Vinberg M; Jørgensen MB; Hageman I; Ehrenreich H; Knudsen GM; Kessing LV; Miskowiak KW
Trials; 2018 Nov; 19(1):611. PubMed ID: 30400939
[TBL] [Abstract][Full Text] [Related]
9. Scopolamine produces larger antidepressant and antianxiety effects in women than in men.
Furey ML; Khanna A; Hoffman EM; Drevets WC
Neuropsychopharmacology; 2010 Nov; 35(12):2479-88. PubMed ID: 20736989
[TBL] [Abstract][Full Text] [Related]
10. [Interest of scopolamine as a treatment of major depressive disorder].
Rigal A; Mouchabac S; Peretti CS
Encephale; 2016 Dec; 42(6):568-573. PubMed ID: 27623122
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
12. Therapy of replenishing and regulating for manic episode in bipolar disorder: study protocol for a prospective, double-blind, randomized controlled trial.
Yang Y; Haining Y; Hongxiao J; Yanzhe N; Di W; Lei Z; Kaijuan Y; Yumeng G; Fei W; Weishuang S; Pei C
J Tradit Chin Med; 2023 Jun; 43(3):594-601. PubMed ID: 37147763
[TBL] [Abstract][Full Text] [Related]
13. Letter to the Editor: CONVERGENCES AND DIVERGENCES IN THE ICD-11 VS. DSM-5 CLASSIFICATION OF MOOD DISORDERS.
Cerbo AD
Turk Psikiyatri Derg; 2021; 32(4):293-295. PubMed ID: 34964106
[TBL] [Abstract][Full Text] [Related]
14. A Randomized Controlled Trial of Intravenous Scopolamine Versus Active-Placebo Glycopyrrolate in Patients With Major Depressive Disorder.
Chen JCC; Sumner RL; Naga VK; Hoeh N; Ayeni HA; Singh V; Wilson A; Campbell D; Sundram F; Muthukumaraswamy SD
J Clin Psychiatry; 2022 Aug; 83(5):. PubMed ID: 35980261
[No Abstract] [Full Text] [Related]
15. Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebo-controlled, proof-of-concept study.
Calabrese JR; Ketter TA; Youakim JM; Tiller JM; Yang R; Frye MA
J Clin Psychiatry; 2010 Oct; 71(10):1363-70. PubMed ID: 20673554
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial.
Calabrese JR; Frye MA; Yang R; Ketter TA;
J Clin Psychiatry; 2014 Oct; 75(10):1054-61. PubMed ID: 25099397
[TBL] [Abstract][Full Text] [Related]
17. Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study).
Azim L; Hindmarch P; Browne G; Chadwick T; Clare E; Courtney P; Dixon L; Duffelen N; Fouweather T; Geddes JR; Goudie N; Harvey S; Helter T; Holstein EM; Martin G; Mawson P; McCaffery J; Morriss R; Simon J; Smith D; Stokes PRA; Walker J; Weetman C; Wolstenhulme F; Young AH; Watson S; McAllister-Williams RH
BMC Psychiatry; 2021 Jul; 21(1):334. PubMed ID: 34225686
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
19. [Early intervention in bipolar affective disorders: Why, when and how].
Pouchon A; Fakra E; Haesebaert F; Legrand G; Rigon M; Schmitt E; Conus P; Bougerol T; Polosan M; Dondé C
Encephale; 2022 Feb; 48(1):60-69. PubMed ID: 34565543
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry P; Hertel P; Such P; Salzman PM; McQuade RD; Nyilas M; Carson WH
J Clin Psychiatry; 2017 Mar; 78(3):324-331. PubMed ID: 28146613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
